Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01516554
Recruitment Status : Terminated (Poor recruitment)
First Posted : January 25, 2012
Last Update Posted : July 8, 2014
University of Manitoba
Consortium of Multiple Sclerosis Centers
Manitoba Medical Service Foundation
Information provided by (Responsible Party):
James Marriott MD, Health Sciences Centre, Winnipeg, Manitoba

Brief Summary:

Fatigue is one of the most frequent symptoms reported by multiple sclerosis (MS) patients and is often a significant source of disability. Unlike normal fatigue, multiple sclerosis related fatigue (MSRF) occurs independently of activity level, suggesting that it is due to dysfunction in the neural pathways that regulate the perception of energy although the precise cause is still not understood. While MSRF can be managed through lifestyle modifications and with drug treatment, these measures are commonly either ineffective or only partially effective.

Administration of the male sex hormone testosterone has been shown to improve energy levels in males with testosterone-deficiency states. Testosterone also reduces fatigue in patients with other medical conditions not associated with low testosterone levels, suggesting that this treatment may also be useful in symptomatic control of MSRF.

This proposed seven-month long clinical trial is designed to test the hypothesis that administration of oral testosterone tablets to male MS patients will result in an improvement of fatigue relative to the administration of placebo tablets. As fatigue is frequently reported by MS patients to be one of their most frustrating and disabling symptoms, any proven additional treatment option for MSRF would be beneficial in improving quality of life.

Condition or disease Intervention/treatment Phase
Multiple Sclerosis Fatigue Drug: Testosterone undecanoate Drug: placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Controlled Crossover Trial Evaluating Oral Testosterone in the Treatment of Fatigue in Male Multiple Sclerosis Patients
Study Start Date : February 2012
Primary Completion Date : January 2014
Study Completion Date : July 2014

Arm Intervention/treatment
Experimental: Testosterone undecanoate Drug: Testosterone undecanoate
40 mg twice daily
Other Name: Andriol
Placebo Comparator: Sugar pill Drug: placebo
twice daily

Primary Outcome Measures :
  1. Change in fatigue (measured with Modified Fatigue Impact Scale [M-FIS]) [ Time Frame: baseline and 12 weeks ]

Secondary Outcome Measures :
  1. Change in fatigue as measured on a visual analog scale (VAS) [ Time Frame: baseline and 12 weeks ]
  2. Quality of life as measured with the Aging Males' Symptoms (AMS) scale [ Time Frame: baseline and 12 weeks ]
  3. Neurological status as measured with the Expanded Disability Status Scale (EDSS) [ Time Frame: baseline and 12 weeks ]
  4. Number of participants with , type and severity of adverse events [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All adult male (18—65 years old) patients are eligible. Patients over > 65 years will be excluded due to increased risk of prostatic hypertrophy or carcinoma in that age group.
  • Patients must have diagnosis of MS using the 2005 revised McDonald Criteria.
  • Patients must have an EDSS score ≤ 6.5.
  • Patients must have a baseline MFIS score ≥ 45 (i.e.: those patients with fatigue).
  • Patients must consent to participate in the study after a discussion of the potential risks and benefits of study participation with their physician. This consent must acknowledge that testosterone administration in MS is experimental and of no proven benefit.
  • Patients must not be on any other agents to specifically treat MSRF (modafinil [Alertec®], amantadine, methylphenidate [Ritalin®, Ritalin SR®, Concerta®].

Exclusion Criteria:

  • Previous or current testosterone administration.
  • Any Health Canada approved indication for testosterone administration.
  • Known hypersensitivity any component of the testosterone undecanoate (Andriol®) formulation including soy.
  • History of relapse in the past 3 months.
  • History of prostate hypertrophy or prostate carcinoma.
  • History of breast cancer.
  • Moderate or severe prostate symptoms (International Prostate Symptom Score [IPSS] ≥ 8).
  • All patients ≥ 50 years old (or ≥ 40 years old if history of prostate cancer/prostate hypertrophy in a first-degree relative or if African-Canadian) will be require a urological assessment including prostate specific antigen (PSA) and digital rectal exam (DRE). Such patients will be excluded if they have a high PSA level or if they have a palpable prostate nodule. Abnormal PSA levels will be determined using standard age-specific cut-off levels.
  • Other serious medical comorbidities including: any other cancer or myelodysplastic syndrome, anemia or polycythemia of any cause, vascular risk factors (including hypertension, dyslipidemia, myocardial infarction, stroke, peripheral vascular disease, atrial fibrillation, other hypercoaguable state or thrombotic risk factor), serious kidney or liver disease, diabetes, obstructive sleep apnea or serious psychiatric disease.
  • History of current alcohol misuse.
  • Recent major surgery.
  • Use of the following medications whose metabolism may be altered by TT: warfarin, corticosteroids, propranolol, cyclosporine or St. John's Wort.81
  • Patients on cyclophosphamide or mitoxantrone (Novantrone®) chemotherapy for MS will be excluded. Patients on other approved disease-modifying therapies for MS (interferon-β1a [Avonex®, Rebif®], interferon-β1b [Betaseron®], glatiramer acetate [Copaxone®] and natalizumab [Tysabri®]) can participate in this trial provided they have been on these therapies for at least six months at a stable dose.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01516554

Canada, Manitoba
Health Sciences Centre
Winnipeg, Manitoba, Canada, R3A1R9
Sponsors and Collaborators
Health Sciences Centre, Winnipeg, Manitoba
University of Manitoba
Consortium of Multiple Sclerosis Centers
Manitoba Medical Service Foundation
Principal Investigator: James J Marriott, MD University of Manitoba

Responsible Party: James Marriott MD, Assistant Professor, Health Sciences Centre, Winnipeg, Manitoba Identifier: NCT01516554     History of Changes
Other Study ID Numbers: 38486
812.14 ( Other Grant/Funding Number: Manitoba Medical Service Foundation )
First Posted: January 25, 2012    Key Record Dates
Last Update Posted: July 8, 2014
Last Verified: July 2014

Keywords provided by James Marriott MD, Health Sciences Centre, Winnipeg, Manitoba:
Multiple Sclerosis

Additional relevant MeSH terms:
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Signs and Symptoms
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents